Premium
Combined Double Lung–Liver Transplantation for Cystic Fibrosis Without Cardio‐Pulmonary By‐Pass
Author(s) -
Corno V.,
Dezza M. C.,
Lucianetti A.,
Codazzi D.,
Carrara B.,
Pinelli D.,
Parigi P. C.,
Guizzetti M.,
Strazzabosco M.,
Melzi M. L.,
Gaffuri G.,
Sonzogni V.,
Rossi A.,
Fagiuoli S.,
Colledan M.
Publication year - 2007
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2007.01945.x
Subject(s) - medicine , liver transplantation , immunosuppression , lung , lung transplantation , transplantation , tacrolimus , cystic fibrosis , liver disease , surgery , respiratory failure , gastroenterology
Sequential bilateral single lung‐liver transplantation (SBSL‐LTx) is a therapeutic option for patients with end stage lung and liver disease (ESLLD) due to cystic fibrosis (CF). A few cases have been reported, all of them were performed with the use of cardio‐pulmonary by‐pass (CPB). We performed SBSL‐LTx in three young men affected by CF. All the recipients had respiratory failure and portal hypertension with hypersplenism. Along with lung transplants, two patients received a whole liver graft and one an extended right graft from an in situ split liver. During transplantation neither CPB nor veno‐venous by‐pass (VVB) were employed. Immunosuppression was based on basiliximab, tacrolimus, steroids and azathioprine. The three recipients are alive with a median follow‐up of 670 days (range 244–1533). Combined SBSL‐LTx is a complex but effective procedure for the treatment of ESLLD due to CF, not necessarily requiring the use of CPB or VVB.